Quest Diagnostics (DGX) Tops Q2 EPS by 2c; beats on guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $248.81 -1.2%
Financial Fact:
Total non-operating expenses, net: -33M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Total non-operating expenses, net: -33M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.30, $0.02 better than the analyst estimate of $2.28. Revenue for the quarter came in at $2.34 billion versus the consensus estimate of $2.25 billion.
GUIDANCE:
Quest Diagnostics sees FY2023 EPS of $8.50-$8.90, versus the consensus of $8.69. Quest Diagnostics sees FY2023 revenue of $9.12-9.22 billion, versus the consensus of $9.06 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Cboe Global Markets (CBOE) Tops Q3 EPS by 21c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
